Abstract
The development of novel T cell therapies to target leukemia has facilitated the translation of this approach for hematologic malignancies. Different methods of manufacturing leukemia-specific T cells have evolved, along with additional measures to increase the safety of this therapy. This is an overview of expanded T cell therapeutics with a focus on how the manufacturing strategies have been refined, and where the research is heading.
Keywords: Cell therapy, leukemia antigens, ex vivo expanded T cells.
Current Drug Targets
Title:Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells
Volume: 18 Issue: 3
Author(s): Conrad R.Y. Cruz and Catherine M. Bollard
Affiliation:
Keywords: Cell therapy, leukemia antigens, ex vivo expanded T cells.
Abstract: The development of novel T cell therapies to target leukemia has facilitated the translation of this approach for hematologic malignancies. Different methods of manufacturing leukemia-specific T cells have evolved, along with additional measures to increase the safety of this therapy. This is an overview of expanded T cell therapeutics with a focus on how the manufacturing strategies have been refined, and where the research is heading.
Export Options
About this article
Cite this article as:
Cruz R.Y. Conrad and Bollard M. Catherine, Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells, Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450117666160209143529
DOI https://dx.doi.org/10.2174/1389450117666160209143529 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chlorambucil Cytotoxicity Reduction in Rats Through Bone Marrow, An In vivo Study
Anti-Cancer Agents in Medicinal Chemistry Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Recent Advances in the Treatment of Multiple Myeloma
Current Pharmaceutical Biotechnology The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
Current Drug Targets The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde
Current Pharmaceutical Design The Role of miRNAs in Plasma Cell Dyscrasias
MicroRNA Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Antitumor Effect of Pomolic Acid in Acute Myeloid Leukemia Cells Involves Cell Death, Decreased Cell Growth and Topoisomerases Inhibition
Anti-Cancer Agents in Medicinal Chemistry New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Current Pharmaceutical Design Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design The Proteasome in Health and Disease
Current Pharmaceutical Design Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Current Genomics Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Current Radiopharmaceuticals Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry